TNF and spondyloarthropathy: Study by Bazin et al. who analysed the gut microbiota composition of 15 patients treated for spondyloarthritis with etanercept, 2 with adalimumab and 1 with infliximab showed that microbiota composition may predict the anti-TNF-α response, with a higher proportion of Burkholderiales order found in future responder patients compared to non-responders [51].